Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

THAT IS HUNT

Financiado

Cerrado

Triggering Haematological Adoptive T cell Immunotherapy Strategies by HUnting No...

Triggering Haematological Adoptive T cell Immunotherapy Strategies by HUnting Novel T cell receptors Recent encouraging clinical results obtained with engineered T lymphocytes and increasing advances in the genome editing field, have opened new opportunities for T-cell receptor (TCR) gene therapy as an immunotherapeutic approach... ver más

31/12/2019

OSR

168K€

Presupuesto del proyecto: 168K€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-31

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OSR

168.28K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CNS2023-144487 Inmunidad, infección e inmunoterapia 200K€ Cerrado

TCRabX Structural basis for the therapeutic efficiency of optimal a... 264K€ Cerrado

PolyAntiTumor Polyclonal anti-tumor immunity by engineered human T cells 2M€ Cerrado

EURE-CART EURopean Endeavour for Chimeric Antigen Receptor Therapies 6M€ Cerrado

OUTSOURCE Outsourcing cancer immunity to healthy donors 2M€ Cerrado

EVOLVE Extracellular Vesicle Internalizing Receptors EVIRs for Ca... 2M€ Cerrado

Duración del proyecto: 33 meses Fecha Inicio: 2017-03-24
Fecha Fin: 2019-12-31

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 168K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Recent encouraging clinical results obtained with engineered T lymphocytes and increasing advances in the genome editing field, have opened new opportunities for T-cell receptor (TCR) gene therapy as an immunotherapeutic approach for cancer. Unfortunately, the broad applicability of this treatment is still hampered by the possible mispairing of exogenous/endogenous TCR chains and by the limited number of high avidity tumor-specific TCRs. While the first issue has been successfully addressed by the hosting lab with the development a TCR gene editing protocol, the identification of novel tumor-specific TCRs is urgently required and this is the aim of my research proposal. We have the unique opportunity to combine the highly complementary expertise of the hosting lab in T-cell biology/genetic transfer and of the applicant on immune repertoire sequencing. We will target acute myeloid leukemia (AML) and hypothesize that by exploiting intrinsic features of AML (i.e. ability of AML blasts to differentiate into potent antigen presenting cells expressing tumor antigens), the functional fingerprint induced by AML on tumor-reactive T-cells, and cutting-edge technologies (i.e. next generation sequencing; ligandome landscape analysis), we will provide a comprehensive immunoprofiling of tumor-specific T-cells and isolate tumor TCR specificities. Results obtained in this study will streamline TCR hunting studies in solid tumors, leading to the generation of a TCR library for different antigens and HLA restrictions, thus rendering TCR gene editing an innovative off-the-shelf treatment available for a high number of cancer patients. Awarding this fellowship will greatly enhance researcher’s career not only by providing the opportunity to widen scientific knowhow and acquire new skills, but also by enabling the researcher to address a major bottleneck currently limiting the full exploitation of the rapidly growing field of cancer immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores